Background/Aim : Incomplete virological response to nucleos(t)ide analogue(NA) experienced chronic hepatitis B (CHB) patients has been observed. This study investigated the efficacy of tenofovir dipivoxil fumarate (TDF) in NA naive and experienced CHB patients at 96 weeks after treatment.
Methods : CHB patients treated with TDF were retrospectively enrolled between Nov 2012 and Nov 2015, and compared NA naive to experienced patients. We assessed virological and biochemical parameters.
Results : A total of 227 patients were included. Median follow-up duration is 48.86 weeks in NA naive group and 46.35 weeks in NA experienced group. Reduction of serum HBV DNA was not significantly different during treatment. The complete virological response (CVR) rate at week 48 and 96 was not different significantly in NA naive and NA experienced groups. (NA naive versus NA experienced, at week 48, 68.5% versus 77.8%; at week 96, 78.7% versus 84.6%) In the NA naive group and NA experienced group, reduction of serum HBV DNA was not different in HBeAg positive and HBeAg negative group. In univariate analysis, the predictive factors for a CVR at weeks 96 was baseline HBV DNA level (CVR group versus no CVR group mean value 18.42x106 IU/mL versus 170.0x106 IU/mL, 95% CI: -163.98x106 ~ -137.97x106).And in NAnaive group, the predictive factor for CVR at 96 week was baseline HBV DNA level (CVR group versus no CVR group mean value 23.02x106 IU/mL versus 170.0x106 IU/mL, 95% CI: -161.05x106 ~ -128.85x106). But in the NA experienced group, any factors were not significantly relation for CVR at week 96.
Conclusion(s) : TDF in treating CHB for more than two year was effective but not different from NA naive and NA experienced groups. The baseline serum HBV DNA level was predictive factors for a CVR at week 96.